About ADP-ribose glycohydrolase MACROD1
ADP-ribose glycohydrolase MACROD1 (MACROD1) is a protein
from Homo sapiens identified by UniProt accession
Q9BQ69, 325 residues long.
MolForge cross-references it against 0 known binders and
175 disease associations.
Target properties
| Protein name | ADP-ribose glycohydrolase MACROD1 |
|---|
| UniProt accession | Q9BQ69 |
|---|
| Gene | MACROD1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 325 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (175)
Diseases linked to this target (Open Targets).
- urate measurement · score 0.45
- BMI-adjusted waist-hip ratio · score 0.32
- triglyceride measurement · score 0.26
- high density lipoprotein cholesterol measurement · score 0.26
- serum gamma-glutamyl transferase measurement · score 0.24
- peripheral neuropathy · score 0.19
- cognitive function measurement · score 0.18
- mean corpuscular volume · score 0.17
- uric acid measurement · score 0.16
- monocyte count · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BQ69-F1 | alphafold | PREDICTED | 82.27 | — |
Amino-acid sequence (325 residues)
MSLQSRLSGR LAQLRAAGQL LVPPRPRPGH LAGATRTRSS TCGPPAFLGV FGRRARTSAG VGAWGAAAVG RTAGVRTWAP LAMAAKVDLS TSTDWKEAKS FLKGLSDKQR EEHYFCKDFV RLKKIPTWKE MAKGVAVKVE EPRYKKDKQL NEKISLLRSD ITKLEVDAIV NAANSSLLGG GGVDGCIHRA AGPLLTDECR TLQSCKTGKA KITGGYRLPA KYVIHTVGPI AYGEPSASQA AELRSCYLSS LDLLLEHRLR SVAFPCISTG VFGYPCEAAA EIVLATLREW LEQHKDKVDR LIICVFLEKD EDIYRSRLPH YFPVA
Explore ADP-ribose glycohydrolase MACROD1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets